The French way of controlling drug costs

Controlling the costs of the Iranian health system: letter to the editor

Controlling information technology costs.

Health care executives are increasingly frustrated by Information Technology (IT). Although our industry is often accused of underinvesting in technology (hospitals average 2-3 percent of their costs in IT, compared to other industry's 8-10 percent), when IT investments are made, they fail to reflect demonstrable return to the bottom line. Yet the effective deployment of technology is so critic...

Controlling the costs of US health care.

With US health expenditure rising past 16% of the country's total economic output—a level almost 50% higher than in any other country—politicians and business executives are scrambling to avoid the bills for America's ragged patchwork of public and private health systems. Opinion polls indicate that health-care bills are now of greater concern to the US public than terrorism, illegal immigratio...

Multivariate data analysis:The French way

Abstract: This paper presents exploratory techniques for multivariate data, many of them well known to French statisticians and ecologists, but few well understood in North American culture. We present the general framework of duality diagrams which encompasses discriminant analysis, correspondence analysis and principal components, and we show how this framework can be generalized to the regre...

Drug development costs when financial risk is measured using the Fama-French three-factor model.

In a widely cited article, DiMasi, Hansen, and Grabowski (2003) estimate the average pre-tax cost of bringing a new molecular entity to market. Their base case estimate, excluding post-marketing studies, was $802 million (in $US 2000). Strikingly, almost half of this cost (or $399 million) is the cost of capital (COC) used to fund clinical development expenses to the point of FDA marketing appr...